J&J Alums Raise $165M Series A for Startup to Develop Biologics for Cancer, Autoimmune Diseases

Third Arc Bio, led by three former Johnson & Johnson executives, is advancing a portfolio of multifunctional antibodies for cancer and inflammatory and immune-mediated diseases.

Scroll to Top